M. Fakih, Metastatic Colorectal Cancer: Current State and Future Directions, Journal of Clinical Oncology, vol.33, issue.16, pp.1809-1833, 2015.
DOI : 10.1200/JCO.2014.59.7633

C. Tournigand, T. André, E. Achille, G. Lledo, M. Flesh et al., FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study, Journal of Clinical Oncology, vol.22, issue.2, pp.229-266, 2004.
DOI : 10.1200/JCO.2004.05.113

D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg et al., Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer, New England Journal of Medicine, vol.351, issue.4, pp.337-382, 2004.
DOI : 10.1056/NEJMoa033025

H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth et al., Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.350, issue.23, pp.2335-2377, 2004.
DOI : 10.1056/NEJMoa032691

M. Furuse, K. Fujita, T. Hiiragi, K. Fujimoto, and S. Tsukita, Claudin-1 and -2: Novel Integral Membrane Proteins Localizing at Tight Junctions with No Sequence Similarity to Occludin, The Journal of Cell Biology, vol.110, issue.7, pp.1539-50, 1998.
DOI : 10.1083/jcb.120.2.477
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2132999/pdf

S. Tsukita, M. Furuse, and M. Itoh, Multifunctional strands in tight junctions, Nature Reviews Molecular Cell Biology, vol.2, issue.4, pp.285-93, 2001.
DOI : 10.1038/35067088

S. Offner, A. Hekele, U. Teichmann, S. Weinberger, S. Gross et al., Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy, Cancer Immunology, Immunotherapy, vol.4, issue.Suppl, pp.431-476, 2005.
DOI : 10.1016/S0002-9440(10)61121-2

G. Krause, L. Winkler, S. Mueller, R. Haseloff, J. Piontek et al., Structure and function of claudins, Biochimica et Biophysica Acta (BBA) - Biomembranes, vol.1778, issue.3, pp.631-676, 2008.
DOI : 10.1016/j.bbamem.2007.10.018
URL : http://doi.org/10.1016/j.bbamem.2007.10.018

M. Lal-nag and P. Morin, The claudins, Genome Biology, vol.10, issue.8, p.235, 2009.
DOI : 10.1186/gb-2009-10-8-235
URL : http://doi.org/10.1186/gb-2009-10-8-235

D. Günzel and M. Fromm, Claudins and Other Tight Junction Proteins, Compr Physiol, vol.65, issue.Suppl. 2, pp.1819-52, 2012.
DOI : 10.1111/j.1749-6632.2009.04925.x

J. Gröne, B. Weber, E. Staub, M. Heinze, I. Klaman et al., Differential expression of genes encoding tight junction proteins in colorectal cancer: frequent dysregulation of claudin-1, -8 and -12, International Journal of Colorectal Disease, vol.156, issue.6, pp.651-660, 2007.
DOI : 10.1016/j.canlet.2004.10.004

Q. Huo, T. Kinugasa, L. Wang, J. Huang, J. Zhao et al., Claudin-1 protein is a major factor involved in the tumorigenesis of colorectal cancer, Anticancer Res, vol.29, pp.851-858, 2009.

N. Miwa, M. Furuse, S. Tsukita, N. Niikawa, Y. Nakamura et al., Involvement of Claudin-1 in the ??-Catenin/Tcf Signaling Pathway and its Frequent Upregulation in Human Colorectal Cancers, Oncology Research, vol.12, issue.11, pp.469-76, 2001.
DOI : 10.3727/096504001108747477

P. Dhawan, A. Singh, N. Deane, Y. No, S. Shiou et al., Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer, Journal of Clinical Investigation, vol.115, issue.7, pp.1765-76, 2005.
DOI : 10.1172/JCI24543DS1
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1150288

A. Singh, A. Sharma, and P. Dhawan, Claudin Family of Proteins and Cancer: An Overview, Journal of Oncology, vol.118, issue.6, p.541957, 2010.
DOI : 10.1158/0008-5472.CAN-06-1680

A. Singh, A. Sharma, J. Smith, M. Krishnan, X. Chen et al., Claudin-1 Up-regulates the Repressor ZEB-1 to Inhibit E-Cadherin Expression in Colon Cancer Cells, Gastroenterology, vol.141, issue.6, pp.58-65, 2011.
DOI : 10.1053/j.gastro.2011.08.038

J. Pope, A. Bhat, A. Sharma, R. Ahmad, M. Krishnan et al., Claudin-1 regulates intestinal epithelial homeostasis through the modulation of Notch-signalling, Gut, vol.8, issue.4, pp.622-656, 2014.
DOI : 10.1186/1476-4598-8-128

J. Pope, R. Ahmad, A. Bhat, M. Washington, A. Singh et al., Claudin-1 overexpression in intestinal epithelial cells enhances susceptibility to adenamatous polyposis coli-mediated colon tumorigenesis, Molecular Cancer, vol.13, issue.1, p.167, 2014.
DOI : 10.1186/1476-4598-13-167
URL : http://doi.org/10.1186/1476-4598-13-167

D. Rio, M. Molina, F. Bascoul-mollevi, C. Copois, V. Bibeau et al., Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan, J Clin Oncol Off J Am Soc Clin Oncol, vol.25, pp.773-80, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00147002

D. Rio, M. Mollevi, C. Vezzio-vie, N. Bibeau, F. Ychou et al., Specific extracellular matrix remodeling signature of colon hepatic metastases, PLoS One, vol.8, p.74599, 2013.

D. Rio, M. Mollevi, C. Bibeau, F. Vie, N. Selves et al., Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies, Eur J Cancer, vol.76, pp.68-75, 2017.

V. Copois, F. Bibeau, C. Bascoul-mollevi, N. Salvetat, P. Chalbos et al., Impact of RNA degradation on gene expression profiles: Assessment of different methods to reliably determine RNA quality, Journal of Biotechnology, vol.127, issue.4, pp.549-59, 2007.
DOI : 10.1016/j.jbiotec.2006.07.032
URL : https://hal.archives-ouvertes.fr/inserm-00147030

L. Marisa, A. De-reyniès, A. Duval, J. Selves, M. Gaub et al., Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value, PLoS Medicine, vol.29, issue.5, p.1001453, 2013.
DOI : 10.1371/journal.pmed.1001453.s016

A. Sadanandam, C. Lyssiotis, K. Homicsko, E. Collisson, W. Gibb et al., A colorectal cancer classification system that associates cellular phenotype and responses to therapy, Nature Medicine, vol.20, issue.5, pp.619-644, 2013.
DOI : 10.1016/S1470-2045(10)70087-5
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3774607

D. Sousa, E. Melo, F. Wang, X. Jansen, M. Fessler et al., Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions, Nat Med, vol.19, pp.614-622, 2013.

J. Guinney, R. Dienstmann, X. Wang, A. De-reyniès, A. Schlicker et al., The consensus molecular subtypes of colorectal cancer, Nature Medicine, vol.228, issue.11, pp.614-622, 2015.
DOI : 10.1186/gb-2004-5-10-r80

N. Rodriguez-salas, G. Dominguez, R. Barderas, M. Mendiola, X. García-albéniz et al., Clinical relevance of colorectal cancer molecular subtypes, Critical Reviews in Oncology/Hematology, vol.109, pp.9-19, 2017.
DOI : 10.1016/j.critrevonc.2016.11.007

V. Granci, F. Bibeau, A. Kramar, F. Boissière-michot, S. Thézénas et al., Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas, European Journal of Cancer, vol.44, issue.15, pp.2312-2320, 2008.
DOI : 10.1016/j.ejca.2008.06.042
URL : https://hal.archives-ouvertes.fr/inserm-00318854

A. Börner, U. Warnken, M. Schnölzer, J. Von-hagen, N. Giese et al., Subcellular protein extraction from human pancreatic cancer tissues, BioTechniques, vol.46, pp.297-304, 2009.

M. Olive, S. Untawale, R. Coffey, M. Siciliano, D. Wildrick et al., Characterization of the DiFi Rectal carcinoma cell line derived from a familial adenomatous polyposis patient, In Vitro Cellular & Developmental Biology - Animal, vol.9, issue.356, pp.239-287, 1993.
DOI : 10.1128/MCB.8.8.3088

P. Dhawan, R. Ahmad, R. Chaturvedi, J. Smith, R. Midha et al., Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation, Oncogene, vol.63, issue.29, pp.3234-3281, 2011.
DOI : 10.1136/gut.2006.094375

L. Marzi, E. Combes, N. Vié, A. Ayrolles-torro, D. Tosi et al., FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer, British Journal of Cancer, vol.38, issue.10, pp.1223-1256, 2016.
DOI : 10.1038/sj.cr.7290257

J. Hecht, J. Douillard, L. Schwartzberg, A. Grothey, S. Kopetz et al., Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer, Cancer Treatment Reviews, vol.41, issue.8, pp.653-662, 2015.
DOI : 10.1016/j.ctrv.2015.05.008

F. Pampaloni, E. Reynaud, and E. Stelzer, The third dimension bridges the gap between cell culture and live tissue, Nature Reviews Molecular Cell Biology, vol.48, issue.10, pp.839-884, 2007.
DOI : 10.1177/002215540004800409

J. Huang, L. Zhang, C. He, Y. Qu, J. Li et al., Claudin-1 enhances tumor proliferation and metastasis by regulating cell anoikis in gastric cancer, Oncotarget, vol.6, issue.3, pp.1652-65, 2015.
DOI : 10.18632/oncotarget.2936
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359322

C. Hackl, S. Man, G. Francia, C. Milsom, P. Xu et al., Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models, Gut, vol.62, issue.2, pp.259-71, 2013.
DOI : 10.1136/gutjnl-2011-301585
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553490

P. Leotlela, M. Wade, P. Duray, M. Rhode, H. Brown et al., Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility, Oncogene, vol.1, issue.26, pp.3846-56, 2007.
DOI : 10.1016/S0002-9440(10)62370-X

P. Bruhns, Properties of mouse and human IgG receptors and their contribution to disease models, Blood, vol.119, issue.24, pp.5640-5649, 2012.
DOI : 10.1182/blood-2012-01-380121

J. Lambert, Drug-conjugated antibodies for the treatment of cancer, British Journal of Clinical Pharmacology, vol.70, issue.8 Suppl., pp.248-62, 2013.
DOI : 10.1007/s00280-012-1934-7

L. Mailly, F. Xiao, J. Lupberger, G. Wilson, A. P. Duong et al., Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody, Nature Biotechnology, vol.33, issue.5, pp.549-54, 2015.
DOI : 10.1053/j.gastro.2012.05.044